BOD Science Ltd
Bod Science Limited operates as a cannabis focused drug development and product innovation company in Australia, the United Kingdom, the European Union, and the United States. The company operates through four segments: Medical, Over The Counter (OTC) Cannabidiol/Hemp, OTC Herbals, and Corporate. It engages in the development of cannabidiol and hemp products for consumers; and development and dis… Read more
BOD Science Ltd (BOD) - Total Assets
Latest total assets as of June 2025: AU$2.60 Million AUD
Based on the latest financial reports, BOD Science Ltd (BOD) holds total assets worth AU$2.60 Million AUD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BOD Science Ltd - Total Assets Trend (2016–2025)
This chart illustrates how BOD Science Ltd’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BOD Science Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
BOD Science Ltd's total assets of AU$2.60 Million consist of 99.9% current assets and 0.2% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 42.3% |
| Accounts Receivable | AU$168.02K | 6.5% |
| Inventory | AU$408.46K | 15.7% |
| Property, Plant & Equipment | AU$0.00 | 0.0% |
| Intangible Assets | AU$3.13K | 0.1% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how BOD Science Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BOD Science Ltd's current assets represent 99.9% of total assets in 2025, a decrease from 100.0% in 2016.
- Cash Position: Cash and equivalents constituted 42.3% of total assets in 2025, down from 99.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 15.7% of total assets.
BOD Science Ltd Competitors by Total Assets
Key competitors of BOD Science Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
BOD Science Ltd - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - BOD Science Ltd generates 1.28x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, BOD Science Ltd generates $9.97 in net profit.
BOD Science Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.34 | 0.30 | 2.21 |
| Quick Ratio | 0.28 | 0.21 | 2.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$-5.10 Million | AU$ -5.30 Million | AU$ 4.61 Million |
BOD Science Ltd - Advanced Valuation Insights
This section examines the relationship between BOD Science Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.45 |
| Latest Market Cap to Assets Ratio | 0.53 |
| Asset Growth Rate (YoY) | 12.6% |
| Total Assets | AU$2.60 Million |
| Market Capitalization | $1.38 Million USD |
Valuation Analysis
Below Book Valuation: The market values BOD Science Ltd's assets below their book value (0.53 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: BOD Science Ltd's assets grew by 12.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for BOD Science Ltd (2016–2025)
The table below shows the annual total assets of BOD Science Ltd from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$2.60 Million | +12.59% |
| 2024-06-30 | AU$2.31 Million | -34.16% |
| 2023-06-30 | AU$3.50 Million | -34.06% |
| 2022-06-30 | AU$5.31 Million | -48.67% |
| 2021-06-30 | AU$10.35 Million | +16.14% |
| 2020-06-30 | AU$8.91 Million | +155.28% |
| 2019-06-30 | AU$3.49 Million | -8.84% |
| 2018-06-30 | AU$3.83 Million | +6.17% |
| 2017-06-30 | AU$3.61 Million | -35.85% |
| 2016-06-30 | AU$5.62 Million | -- |